Advances in immunotherapy for the treatment of cutaneous T-cell lymphoma
A Pelcovits, TA Ollila, AJ Olszewski - Cancer Management and …, 2023 - Taylor & Francis
Abstract Cutaneous T-Cell Lymphoma (CTCL) is a heterogenous disease that consists of
distinct clinicopathologic entities and presentations requiring a unique and expert approach …
distinct clinicopathologic entities and presentations requiring a unique and expert approach …
“Next top” mouse models advancing CTCL research
This review systematically describes the application of in vivo mouse models in studying
cutaneous T-cell lymphoma (CTCL), a complex hematological neoplasm. It highlights the …
cutaneous T-cell lymphoma (CTCL), a complex hematological neoplasm. It highlights the …
[PDF][PDF] CD38 targeting in aggressive, treatment-refractory cutaneous T-cell lymphomas
ADM, AB, MBat, and MBag are named as inventors on a pending patent application
regarding the use of CD38 as therapeutic target for the treatment of T-cell lymphomas …
regarding the use of CD38 as therapeutic target for the treatment of T-cell lymphomas …
Novel and multiple targets for chimeric antigen receptor-based therapies in lymphoma
Y Pang, N Ghosh - Frontiers in Oncology, 2024 - frontiersin.org
Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 in B-cell non-Hodgkin
lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies …
lymphoma (NHL) validates the utility of CAR-based therapy for lymphomatous malignancies …
Education and empowering special forces to eradicate secret defectors: immune system-based treatment approaches for mature T-and NK-cell Malignancies
T Braun, A Schrader - Cancers, 2023 - mdpi.com
Simple Summary Mature T-and NK-cell leukemia/lymphoma (MTCL/L) are a heterogeneous
group of rare, mostly poor prognostic neoplastic entities. In the past, immunotherapeutic …
group of rare, mostly poor prognostic neoplastic entities. In the past, immunotherapeutic …